PDCD1 and melanoma: In phase I clinical trials, T-Vec with ipilimumab (a cytotoxic T lymphocyte-associated antigen 4 [CTLA-4] monoclonal antibody [mAb]) or pembrolizumab (a programmed cell death protein 1 [PD-1] mAb) has shown excellent efficacy in melanoma patients.5